Financial Performance - The company reported revenue of HKD 20.6 million for the six months ended June 30, 2023, compared to HKD 13.6 million in the same period of 2022, representing a year-over-year increase of 51.5%[5] - Gross profit for the same period was HKD 11.4 million, with a gross margin of 55.3%, up from HKD 5.9 million and a gross margin of 43.0% in 2022[5] - The consolidated loss attributable to the company was HKD 3.4 million, compared to HKD 2.4 million in 2022, indicating a worsening of 41.7%[5] - The company reported a loss before tax of HKD 2,658,000, compared to a loss of HKD 2,436,000 in the previous year, indicating a deterioration in performance[26] - Total comprehensive loss for the period was HKD 3,401,000, compared to HKD 2,446,000 in the same period last year[26] - Basic and diluted loss per share was HKD 1.2, an increase from HKD 0.8 in the previous year[26] - For the six months ended June 30, 2023, the company reported a net loss of HKD 3,401,000, compared to a net loss of HKD 2,446,000 for the same period in 2022[36] Assets and Liabilities - Total assets as of June 30, 2023, were HKD 41.5 million, an increase from HKD 24.6 million as of December 31, 2022[6] - Current assets increased to HKD 36,146,000 as of June 30, 2023, from HKD 18,605,000 at the end of 2022, reflecting improved liquidity[28] - Total liabilities as of June 30, 2023, were HKD 385,239,000, compared to HKD 366,407,000 at the end of 2022, showing an increase in financial obligations[28] - Total liabilities increased to HKD 388,880,000 as of June 30, 2023, compared to HKD 368,595,000 at the end of 2022[43] Cash Flow and Financing - The net cash inflow for the six months ended June 30, 2023, was HKD 2.6 million, compared to a cash outflow of HKD 2.1 million in the same period of 2022[6] - The company reported cash used in operating activities of HKD 8,971,000 for the six months ended June 30, 2023, compared to HKD 5,109,000 for the same period in 2022[33] - The company has secured financing of HKD 8,000,000 and HKD 12,000,000 from investors to support its operational costs and business activities[37] - The company is assessing its ability to continue as a going concern, considering its future cash flow and financing options[36] Business Operations - Revenue from the medical and health lifestyle business for the six months ended June 30, 2023, was HKD 20,599,000, a significant increase from HKD 13,615,000 in the same period of 2022, representing a growth of approximately 51.2%[38] - The company continues to develop its medical and health lifestyle business to improve operational cash flow[37] - The company incurred a pre-tax loss of HKD 2,658,000 for the medical and health lifestyle segment, after accounting for unallocated corporate expenses of HKD 4,829,000 and unallocated finance costs of HKD 5,824,000[40] Corporate Governance - The board is committed to maintaining high standards of corporate governance, despite the CEO position being vacant[22][24] - The company has not conducted any capital raising activities during the reporting period[8] - The company has not granted any share options or share awards during the six months ended June 30, 2023[20][26] - The board did not recommend any interim dividend for the six months ended June 30, 2023, consistent with the previous year[48] Other Financial Metrics - The company's cash and cash equivalents increased by HKD 2,574,000, reaching HKD 5,670,000 at the end of June 2023, compared to HKD 1,546,000 at the end of June 2022[33] - Trade receivables surged to HKD 10,237,000, a significant increase from HKD 1,037,000 in the previous year, indicating higher sales volume[28] - The company recorded interest income of HKD 153,000 from bank balances, a significant increase from HKD 1,000 in the previous year[45] - The total depreciation expense for the six months ended June 30, 2023, was HKD 662,000, up from HKD 565,000 in the prior year[47]
京玖康疗(00648) - 2023 - 中期财报